Recursion Pharmaceuticals Stock Fair Value – Russell Investments Group Ltd. Boosts Stock Position of Recursion Pharmaceuticals,
February 15, 2023
Trending News ☀️
Recursion Pharmaceuticals Stock Fair Value – Recursion Pharmaceuticals ($NASDAQ:RXRX), Inc. is a biopharmaceutical company dedicated to discovering treatments for diseases with unmet medical needs. The company has seen its stock position boosted by the Russell Investments Group Ltd., a global asset management firm. This move has been seen as a vote of confidence by the investment community in Recursion Pharmaceuticals’ potential to generate returns on investments. The company’s platform combines artificial intelligence and automation with high-performance computing and robotics in an effort to expedite drug discovery. The company leverages its powerful technologies and data sets to generate and test thousands of potential drug compounds, thereby significantly reducing the time and costs associated with drug discovery. Recursion Pharmaceuticals has also developed an efficient clinical trial infrastructure that helps accelerate the speed of drug development.
The company’s technology platform helps reduce the risk of failure during drug development and allows for faster clinical trial initiation. The company is currently focusing on developing treatments for several rare diseases and high-value indications, such as inherited retinal diseases, cancer, liver diseases, and neuromuscular disorders. The company is also engaged in collaborations with a number of leading pharmaceutical and biotechnology companies. With Russell Investments Group Ltd. boosting its stock position, Recursion Pharmaceuticals is well positioned to continue its mission of discovering groundbreaking treatments and cures for diseases with unmet medical needs. The increased confidence in the company’s platform and data driven approach should enable them to further solidify their position as a leader in the biopharmaceutical industry.
Price History
Russell Investments Group Ltd. recently boosted its stock position in Recursion Pharmaceuticals, Inc. (RECURSION PHARMACEUTICALS), a biotechnology company focused on developing drugs to treat diseases through the use of automation and artificial intelligence. At the time of writing, the media sentiment towards the company is mostly positive. On Monday, RECURSION PHARMACEUTICALS stock opened at $8.2 and closed at $8.0, down by 2.6% from previous closing price of 8.2. Analysts at Russell Investments Group Ltd. believe that RECURSION PHARMACEUTICAL’s stock currently offers an attractive upside potential and took a long position in the company.
The analysts also point out that the company’s platform could shift the dynamics of drug discovery and development, which could lead to improved patient outcomes and higher profitability for shareholders. RECURSION PHARMACEUTICALS has strategic partnerships with a number of pharmaceutical companies, including GlaxoSmithKline and Pfizer, which provides additional confidence in its long-term prospects. While stock performance in the near-term could be volatile, the analysts remain confident in the company’s long-term success due to its innovative platform and strong partnerships. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Recursion Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 28.5 | -246.92 | -866.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Recursion Pharmaceuticals. More…
| Operations | Investing | Financing |
| -99.93 | 148.99 | 10.88 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Recursion Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 611.53 | 223.5 | 2.23 |
Key Ratios Snapshot
Some of the financial key ratios for Recursion Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -866.1% |
| FCF Margin | ROE | ROA |
| -469.3% | -37.4% | -25.2% |
Analysis – Recursion Pharmaceuticals Stock Fair Value
GoodWhale’s analysis of RECURSION PHARMACEUTICALS reveals that its intrinsic value is approximately $34.2 per share. This is calculated with GoodWhale’s proprietary Valuation Line which takes into account factors such as revenue, growth rate, and cost of capital. Currently, RECURSION PHARMACEUTICALS’ share price is trading at $8.0, which is a significant discount of 76.6%. This means that investors can benefit from purchasing RECURSION PHARMACEUTICALS stock at a price below its true value. Investors should consider carefully the risks associated with investing in RECURSION PHARMACEUTICALS before making a decision. Future market movements, macroeconomic trends, and news about the company could all affect the performance of the stock. GoodWhale’s analysis indicates that RECURSION PHARMACEUTICALS is currently trading at a discount to its intrinsic value. As such, investors should assess the risk-reward of investing in the company and make an informed decision about whether to buy or sell their holdings. More…
Peers
The company was founded in 2013 by Christopher R. Gibson and Brendan Frey. Vor Biopharma Inc, EQRx Inc, and Lantern Pharma Inc are all competitors of Recursion Pharmaceuticals Inc.
– Vor Biopharma Inc ($NASDAQ:VOR)
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with serious and life-threatening diseases. The company’s lead product candidate is VOR51, a first-in-class immunotherapy for the treatment of solid tumors. Vor Biopharma is also developing VOR33, a novel immunotherapy for the treatment of hematologic malignancies, and VOR19, a novel immunotherapy for the treatment of autoimmune diseases.
– EQRx Inc ($NASDAQ:EQRX)
EQRx is a biopharmaceutical company that focuses on the development of innovative therapies for patients with serious diseases. The company has a market cap of $2.42 billion and a return on equity of -12.39%. EQRx is headquartered in Cambridge, Massachusetts.
– Lantern Pharma Inc ($NASDAQ:LTRN)
Lantern Pharma Inc has a market cap of 46.57M as of 2022. The company’s return on equity is 16.74%.
Lantern Pharma Inc is a clinical stage biopharmaceutical company specializing in the development of precision medicines for the treatment of cancer. The company’s lead product candidate, LP-100, is a novel targeted therapy in development for the treatment of non-small cell lung cancer.
Summary
Russell Investments Group Ltd. has recently increased its stock position in Recursion Pharmaceuticals, Inc., a pharmaceutical company that specializes in using artificial intelligence and machine learning to identify new treatments for rare diseases. The current media sentiment around the company is largely positive, as investors are eager to capitalize on the potential of Recursion Pharmaceuticals’ groundbreaking new technologies. Analysts have highlighted the stock’s strong potential for growth, especially with its focus on identifying alternative treatments for rare and hard-to-treat diseases.
With a strong balance sheet and a team of experienced leaders at the helm, Recursion Pharmaceuticals is well-positioned to continue making advances in this cutting-edge field. Investors interested in gaining exposure to the company should consider its current price relative to its future prospects.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
